This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Edwards operated in 'secrecy' to stifle competition and subvert antitrust laws, US FTC argues

By Wesley Brown ( December 16, 2025, 23:45 GMT | Insight) -- The US Federal Trade Commission argued in its proposed findings of fact and conclusions of law that Edwards Lifesciences operated in “secrecy” and designed its acquisitions of JenaValve and JC Medical in a way to stifle competition and subvert antitrust laws. The government asserts that Edwards acquiring JenaValve, after acquiring JC Medical, would give the device maker control over the entire market for transcatheter aortic valve replacement devices to treat aortic regurgitation.The US Federal Trade Commission argued in its proposed findings of fact and conclusions of law that Edwards Lifesciences operated in “secrecy” and designed its acquisitions of JenaValve and JC Medical in a way to stifle competition and subvert antitrust laws....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login